CSL Ltd. (CSL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 20, 2025

$170.54

P/E Ratio

32.89

Market Cap

$82.89B

Jan 29, 2024Mar 1, 2024Apr 5, 2024May 9, 2024Jun 14, 2024Jul 18, 2024Aug 21, 2024Sep 25, 2024Oct 30, 2024Dec 3, 2024Jan 20, 2025$170.00$180.00$190.00$200.00$210.00
  • CSL
Description

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Metrics

Overview

  • HQMelbourne, VI
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerCSL
  • Price$170.535394-0.20%

Trading Information

  • Market cap$82.89B
  • Float99.94%
  • Average Daily Volume (1m)491,976
  • Average Daily Volume (3m)642,638
  • EPS$8.35

Company

  • Revenue$22.42B
  • Rev growth (1yr)14.46%
  • Net income$4.03B
  • Gross margin48.68%
  • EBITDA margin31.59%
  • EBITDA$7.08B
  • EV$162.05B
  • EV/Revenue7.23
  • P/E32.89
  • P/S5.94
  • P/B5.10
Documents